Robert Blum

speaker

321 appearances 1 recordings 1 series first heard Feb 2026 last heard 3 Feb

Robert Blum’s voice in public audio — every appearance, attributed to the second.

Trend

recordings per month · last 12 months

Recordings per month over the last 12 months — 1 in all, peaking in Feb 2026 with 1.

Appearances

newest first · ▶ plays the moment

Vanguards of Healthcare by Bloomberg Intelligence · Precision Cardiology With Cytokinetics · 3 Feb 2026 podcast

placebo response rate that tracks study to study with KCCQ.

So we believe we've powered our study, Acacia, knowing that there is a placebo response rate, typically between four and six, and where we believe if afecamptin or mycorzo is going to be effective in this population, we've designed the right study.

So we haven't yet commented on the baseline characteristics in Acacia, but I will say that those individuals here at Sato Kinetics who designed both Redwood and Acacia did what one should expect of them in clinical research.

They piloted a dose strategy that is the same strategy we took from phase two to phase three.

They're going to the same centers that have experience with patients with NHCM and these efficacy endpoints.

And what we know from having done studies in these centers is experience matters.

Experience amongst the investigator, but also their office personnel and their training.

As it relates to KCCQ,

as I mentioned, the training of the KCCQ matters.

And whether we're doing that in the United States, Europe, or even China, we're working with that person who designed the KCCQ to conduct the training, understanding the failure modes.

And our

colleagues, internal to cytokinetics, who are overseeing the conduct of this study, they look, as they are experienced to do, at every single echo, and they ask questions of investigators if they have any concerns about whether a patient may not meet criteria.

And why do I mention that?

Because in NHCM, as you mentioned before, absent a gradient, an echo can tell you important things.

And it can also raise a question as to whether there may be a patient phenocopying to NHCM, but maybe they have amblyodosis or some form of HFPEF.

So it's imperative that we ensure we've screened in the right patients and screened out the wrong patients as they know well to do.

Yes, I think so.

And also conduct of the measures of exercise stamina or fatigue, which includes the peak VO2.

How is that measured?

And how do we ensure quality control of that?

Showing 221–240 of 321 · page 12 of 17